Table 1 Baseline features of rheumatoid arthritis cohort
Parameters | RA patients (n = 25) |
|---|---|
Age (years); mean ± SD | 41.32 ± 10.04 |
Gender (number, percentage) | |
 -Females | 16 (64%) |
 -Males | 9 (36%) |
Disease onset (years); mean ± SD | 33 ± 11.29 |
Disease duration (years); mean ± SD | 8.32 ± 5.45 |
Morning stiffness (min); mean ± SD | 41 ± 25.81 |
Swollen joints | 6.72 ± 3.38 |
ESR (mm/h); mean ± SD | 65.76 ± 29.24 |
CRP (mg/l); mean ± SD | 53.61 ± 24.91 |
DAS28; mean ± SD | 5.91 ± 0.98 |
RF (IgM) positivity | 21 (84.0%) |
RF (IU/ml); mean ± SD | 133.76 ± 88.21 |
Anti-CCP positivity | 15 (60%) |
Anti-CCP (RU/ml); mean ± SD | 322.20 ± 112.60 |
bDMARDs at inclusion | |
 -Infliximab (remicade) | 9 (36%) |
 -Etanercept (enbrel) | 7 (28%) |
 -Adalimumab (humera) | 5 (20%) |
 -Tocilizumab (actemra) | 3 (12%) |
 -Golimumab (simponi) | 1 (4%) |